Hutchmed China appoints Dr. Dan Eldar to its Board of Directors as Chairman

– CHINA, Hong Kong –  HUTCHMED (China) Limited (Nasdaq:​ HCM /LON:​ HCM / HKEX:​ 13) today announced the appointment of Dr. Dan Eldar (Ph.D.) as Chairman of the Board of Directors effective on May 17, 2024, succeeding Simon To who steps down from the Board.
(b) .

About Dr. Dan Eldar

Dr. Dan Eldar has been a Non-executive Director of the Company since 2016. He has over 30 years of experience as a senior executive, leading global operations in biotechnology, healthcare, telecommunications, and water. He is an executive director of Hutchison Water Israel E.P.C Ltde of CK Hutchison Associates focusing on large-scale desalination and hydroelectric projects.

Dr. Dan Eldar received a Doctor of Philosophy degree in Government from Harvard University, a Master of Arts degree in Government from Harvard University, a Master of Arts degree in Political Science and Public Administration from the Hebrew University of Jerusalem, and a Bachelor of Arts degree in Political Science from the Hebrew University of Jerusalem.


HUTCHMED is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since its inception, HUTCHMED has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.